208 related articles for article (PubMed ID: 30323548)
21. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
Malhotra R; Devries DK; Luchs J; Kabat A; Schechter BA; Shen Lee B; Shettle L; Smyth-Medina R; Ogundele A; Darby C; Bacharach J; Karpecki P
Cornea; 2019 Oct; 38(10):1259-1265. PubMed ID: 31306284
[TBL] [Abstract][Full Text] [Related]
22. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
[TBL] [Abstract][Full Text] [Related]
23. The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye.
Stonecipher KG; Torkildsen GL; Ousler GW; Morris S; Villanueva L; Hollander DA
Clin Ophthalmol; 2016; 10():887-95. PubMed ID: 27257373
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of cyclosporine (0.05% versus 0.09%) in dry eye disease. Is it the strength of cyclosporin that really matters?
Rajpoot M; Singh D; Pandey K; Bhargava R
Nepal J Ophthalmol; 2022 Jul; 14(28):64-77. PubMed ID: 37609968
[TBL] [Abstract][Full Text] [Related]
25. TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China.
Dong Y; Wang S; Cong L; Zhang T; Cheng J; Yang N; Qu X; Li D; Zhou X; Wang H; Lee M; Wang M; Chen S; Ousler GW; Chen X; Xie L
Int Ophthalmol; 2022 Aug; 42(8):2459-2472. PubMed ID: 35192105
[TBL] [Abstract][Full Text] [Related]
26. Water-Free Cyclosporine Ophthalmic Solution vs Vehicle for Dry Eye Disease: A Randomized Clinical Trial.
Peng R; Jie Y; Long Q; Gong L; Zhu L; Zhong X; Zhao S; Yan X; Gu H; Wu H; Li G; Zhang K; Krösser S; Xu R; Hong J
JAMA Ophthalmol; 2024 Apr; 142(4):337-343. PubMed ID: 38451509
[TBL] [Abstract][Full Text] [Related]
27. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease.
Clark D; Sheppard J; Brady TC
J Ocul Pharmacol Ther; 2021 May; 37(4):193-199. PubMed ID: 33450164
[No Abstract] [Full Text] [Related]
28. Efficacy and Safety of the Long-Acting Diquafosol Ophthalmic Solution DE-089C in Patients with Dry Eye: A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study.
Hori Y; Oka K; Inai M
Adv Ther; 2022 Aug; 39(8):3654-3667. PubMed ID: 35716319
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A Multicenter Phase II Clinical Study.
Peng WY; Chen RX; Dai H; Zhu L; Li Y; Gao ZQ; Li XY; Zhou SY
Clin Ther; 2021 Mar; 43(3):613-628. PubMed ID: 33546885
[TBL] [Abstract][Full Text] [Related]
30. One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.
Baudouin C; de la Maza MS; Amrane M; Garrigue JS; Ismail D; Figueiredo FC; Leonardi A
Eur J Ophthalmol; 2017 Nov; 27(6):678-685. PubMed ID: 28708219
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
Evans D; Kenyon K; Ousler G; Watson M; Vollmer P; McLaurin EB; Torkildsen G; Winters J; Dodd J; Jordan R; Wills ST; Spana C
J Ocul Pharmacol Ther; 2023 Nov; 39(9):600-610. PubMed ID: 37677000
[No Abstract] [Full Text] [Related]
32. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye.
Kinoshita S; Oshiden K; Awamura S; Suzuki H; Nakamichi N; Yokoi N;
Ophthalmology; 2013 Jun; 120(6):1158-65. PubMed ID: 23490326
[TBL] [Abstract][Full Text] [Related]
33. Association between systemic activity ındex and dry eye severity in patients with primary Sjögren syndrome.
Ozek D; Kemer OE; Omma A
Arq Bras Oftalmol; 2019; 82(1):45-50. PubMed ID: 30403265
[TBL] [Abstract][Full Text] [Related]
34. Effects of corneal nerve density on the response to treatment in dry eye disease.
Kheirkhah A; Dohlman TH; Amparo F; Arnoldner MA; Jamali A; Hamrah P; Dana R
Ophthalmology; 2015 Apr; 122(4):662-8. PubMed ID: 25542519
[TBL] [Abstract][Full Text] [Related]
35. Varenicline solution nasal spray for dry eye disease in Chinese patients: a randomized phase 3 trial.
Tian L; Jin X; Wang J; Xu Y; Lu C; Zhao S; Zhu Q; Dai H; Gu H; Zhang M; Wang L; Lu X; Ma L; Zhu L; Zeng Q; Zhang H; Fu Y; Li S; Tao L; Ren Q; Ding F; Zhang S; Zhu S; Li Z; Jie Y
Lancet Reg Health West Pac; 2024 Apr; 45():101032. PubMed ID: 38440130
[TBL] [Abstract][Full Text] [Related]
36. The DEPOT Study (Dry Eye Prescription Options for Therapy): Assessing the Efficacy and Safety of OTX-DED (Dexamethasone Ophthalmic Insert 0.3 mg) for Intracanalicular Use Compared with Loteprednol Suspension for the Treatment of Episodic Dry Eye.
Hovanesian JA; Keyser A; Berdy G; Sorensen R
Clin Ophthalmol; 2022; 16():3841-3849. PubMed ID: 36438591
[TBL] [Abstract][Full Text] [Related]
37. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
38. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
[TBL] [Abstract][Full Text] [Related]
39. Topical Fluorometholone Protects the Ocular Surface of Dry Eye Patients from Desiccating Stress: A Randomized Controlled Clinical Trial.
Pinto-Fraga J; López-Miguel A; González-García MJ; Fernández I; López-de-la-Rosa A; Enríquez-de-Salamanca A; Stern ME; Calonge M
Ophthalmology; 2016 Jan; 123(1):141-53. PubMed ID: 26520171
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease.
Yeu E; Goldberg DF; Mah FS; Beckman KA; Luchs JI; Solomon JD; White DE; Gupta PK
Clin Ophthalmol; 2019; 13():887-894. PubMed ID: 31213759
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
